Severe Asthma: Where Do We Stand?

Price: FREE

Severe asthma poses significant disease-related and economic burdens in the United States. Challenges in practice include how to define “severe asthma” for a given patient, knowing which are the right tests to perform and when, and having a better understanding of a patient’s asthma phenotype. Determining asthma phenotype is the foundation of precision medicine for this persistent, often difficult to treat disease. Without an understanding of a patient’s asthma phenotype, it is difficult to optimize treatment and gain ground on outcomes such as daily symptoms, exacerbations, and hospitalizations. It is also evident that determining when to start a biologic therapy or use bronchial thermoplasty in real-world practice may be unclear. In the absence of clear guidelines addressing these specific issues, an expert panel convened to develop a consensus on a definition for severe asthma as well as guiding principles for biomarker testing, and the use of newer biologics and bronchial thermoplasty in these patients. This webcast presents the expert panel’s consensus on guiding principles and other practical issues related to the treatment of severe asthma.

Target Audience

Practicing Allergists / Immunologists

Learning Objectives

After viewing the video recording, learners should be able to…

  • Discuss current unmet medical needs in patients with severe asthma
  • Describe asthma phenotypes and endotypes and evaluate the viability of routine biomarker testing for asthma subtypes in practice
  • Outline updated therapeutic decision-making guidance for patients with severe asthma that is based on biomarkers and other patient disease characteristics


The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Commercial Support
This activity was supported by an independent educational grant from Boston Scientific.

Additional information

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewers, and other individuals in a position to control or influence the content of an activity must disclose all relevant financial relationships with any commercial interest that have occurred within the past 12 months. The ACCME defines a “commercial interest” as any entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit All identified conflicts of interest must be resolved and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure be provided to the learners prior to the start of the activity.

Individuals with no relevant financial relationships must also inform the learners that no relevant financial relationships exist. Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI.

All identified conflicts of interest have been resolved.

Michael Blaiss, MD, FACAAI, Planner, Faculty, Speaker
Consultant, Fees: ALK, Pfizer, PMD Healthcare, RxBands, Stallergenes

Mario Castro, MD, MPH, Faculty, Speaker
Consultant, Fees: Boston Scientific, Genentech, Holaira, Neostem, Teva
Speaker, Honorarium: Boehringer-Ingelheim, Boston Scientific, Genentech, GlaxoSmithKline, Teva
Advisory Committee, Fees: Genentech, GlaxoSmithKline
Independent Contractor, Royalties: Elsevier

Bradley E. Chipps, MD, Faculty
Consultant, Fees:
Speaker, Honorarium:
Advisory Committee, Fees:

Michael B. Foggs, MD, Faculty
Consultant, Fees: AstraZeneca, Boehringer Ingelheim, Boston Scientific, Meda, Merck, Mylan
Speaker, Honorarium: Boehringer Ingelheim, Meda

Reynold Panettieri, MD, Faculty
Consultant, Fees: AstraZeneca, Teva
Speaker, Honorarium: AstraZeneca, Novartis, Teva
Advisory Committee, Fees: AstraZeneca

Myron Zitt, MD, Faculty
Consultant, Fees: Boston Scientific
Speaker, Honorarium: Boston Scientific, Meda
Advisory Committee, Fees: Boehringer Ingelheim

Ray Rodriguez, MD, Reviewer
Speaker, Honorarium: Shire

The following speaker has no relevant financial relationships to disclose:

Sean M. Gregory, PhD, Medical Writer

Course summary
Available credit: 
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Attendance
Course opens: 
Course expires: 

Michael Blaiss, MD, FACAAI
Executive Medical Director
American College of Allergy, Asthma & Immunology
Clinical Professor of Pediatrics
Medical College of Georgia
Augusta, Georgia


Mario Castro, MD, MPH
Alan A. and Edith L. Wolff Professor
Pulmonary and Critical Care Medicine
Professor of Medicine,
Pediatrics, and Radiology
Washington University School of Medicine
St. Louis, Missouri

Available Credit

  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Attendance
Please login or create an account to take this course.